Details

Autor(en) / Beteiligte

• Gerhauser, Clarissa
• Favero, Francesco
• Risch, Thomas
• Simon, Ronald
• Feuerbach, Lars
• Assenov, Yassen
• Heckmann, Doreen
• Sidiropoulos, Nikos
• Waszak, Sebastian M.
• Hübschmann, Daniel
• Urbanucci, Alfonso
• Girma, Etsehiwot G.
• Kuryshev, Vladimir
• Klimczak, Leszek J.
• Saini, Natalie
• Stütz, Adrian M.
• Weichenhan, Dieter
• Böttcher, Lisa-Marie
• Toth, Reka
• Hendriksen, Josephine D.
• Koop, Christina
• Lutsik, Pavlo
• Matzk, Sören
• Warnatz, Hans-Jörg
• Amstislavskiy, Vyacheslav
• Feuerstein, Clarissa
• Raeder, Benjamin
• Bogatyrova, Olga
• Schmitz, Eva-Maria
• Hube-Magg, Claudia
• Kluth, Martina
• Huland, Hartwig
• Graefen, Markus
• Lawerenz, Chris
• Henry, Gervaise H.
• Yamaguchi, Takafumi N.
• Malewska, Alicia
• Meiners, Jan
• Schilling, Daniela
• Reisinger, Eva
• Eils, Roland
• Schlesner, Matthias
• Strand, Douglas W.
• Bristow, Robert G.
• Boutros, Paul C.
• von Kalle, Christof
• Gordenin, Dmitry
• Sültmann, Holger
• Brors, Benedikt
• Sauter, Guido
• Plass, Christoph
• Yaspo, Marie-Laure
• Korbel, Jan O.
• Schlomm, Thorsten
• Weischenfeldt, Joachim

Titel

Molecular Evolution of Early-Onset Prostate Cancer Identifies Molecular Risk Markers and Clinical Trajectories

Ist Teil von

• Cancer cell, 2018-12, Vol.34 (6), p.996-1011.e8

Ort / Verlag

United States: Elsevier Inc

Erscheinungsjahr

2018

Quelle

MEDLINE

Beschreibungen/Notizen

• Identifying the earliest somatic changes in prostate cancer can give important insights into tumor evolution and aids in stratifying high- from low-risk disease. We integrated whole genome, transcriptome and methylome analysis of early-onset prostate cancers (diagnosis ≤55 years). Characterization across 292 prostate cancer genomes revealed age-related genomic alterations and a clock-like enzymatic-driven mutational process contributing to the earliest mutations in prostate cancer patients. Our integrative analysis identified four molecular subgroups, including a particularly aggressive subgroup with recurrent duplications associated with increased expression of ESRP1, which we validate in 12,000 tissue microarray tumors. Finally, we combined the patterns of molecular co-occurrence and risk-based subgroup information to deconvolve the molecular and clinical trajectories of prostate cancer from single patient samples. [Display omitted] •Clock-like mutation process attributed to APOBEC3 mediates earliest mutations in PC•Identification of four molecular subgroups that stratifies intermediate-risk disease•Rearrangements at the ESRP1 locus associated with aggressive and proliferative cancer•Development of method to predict clinical trajectories of PC from DNA sequencing data Gerhauser et al. molecularly characterize prostate cancers diagnosed before 56 years old, which reveals an APOBEC-driven mutational process and identifies an aggressive subgroup with increased expression of ESRP1. They develop a framework to predict the order of somatic alterations and clinical outcome.